Sebastian, T., Hashmi, H., Firestone, R., Jurgens, E., Rajeeve, S., Farzana, T., Merz, M., Tan, C., Maclachlan, K., Maura, F., Korde, N., Hassoun, H., Shah, U., Hultcrantz, M., Landau, H., Scordo, M., Lesokhin, A., Derkach, A., Nemirovsky, D., Giralt, S., Mailankody, S., Usmani, S. (2025). Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma. Blood. https://doi.org/10.1182/blood-2025-2291